1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Biogen Inc.

Biogen Inc.

BIIB.SW
Biogen Inc.CH flagSwiss Exchange
141.03
USD
-6.43
- -
20.82BMarket Cap
Biogen Inc.
BIIB.SW
(Swiss Exchange)

Recent

price

141.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
29.26
41.05
- -
- -
- -
- -
- -
83.56
73.65
70.02
67.97
66.46
67.51
67.72
Revenue per Share
- -
- -
- -
7.86
12.42
- -
- -
- -
- -
- -
24.86
10.44
20.97
8.02
11.21
8.83
9.35
Basic EPS, GAAP
- -
- -
- -
-4.91
11.11
- -
- -
- -
- -
- -
22.86
22.43
7.85
8.54
17.28
13.44
15.78
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
26.8
39.28
- -
- -
- -
- -
- -
86.86
93.31
113.33
121.82
132.28
140.29
142.23
Book Value per Share
- -
- -
- -
12.3
21.26
- -
- -
- -
- -
- -
11.43
19.97
39.84
1.5
3.75
17.66
21.19
Tangible Book Value per Share
- -
- -
- -
237
236
- -
- -
- -
- -
- -
161
149
145
145
146
146
147
Basic Weighted Avg Shares
4,716
5,049
5,516
6,932
9,703
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,173
9,836
9,676
9,891
9,937
Sales/Revenue/Turnover
33.27
35.25
33.33
35.92
40.37
46.59
49.39
45.05
44.61
48.93
33.07
25.57
28.52
18.79
23.57
24.96
23.18
Operating Margin (%)
356
359
366
532
688
600
683
1,081
650
465
457
488
518
495
673
780
801
Depreciation Expense
1,005
1,234
1,380
1,862
2,935
3,547
3,703
2,539
4,431
5,888
4,001
1,556
3,047
1,161
1,632
1,293
1,372
Net Income, GAAP
26.94
25.98
25.37
24.23
25.08
24.37
25.08
47.94
24.16
16.25
19.66
3.01
17.62
10.43
14.37
16.94
15.47
Effective Tax Rate (%)
21.31
24.45
25.02
26.86
30.25
32.95
32.34
20.69
32.93
40.96
29.76
14.17
29.95
11.81
16.87
13.07
13.81
Profit Margin (%)
1,490
2,063
1,587
1,427
2,317
4,123
5,312
4,505
4,346
3,518
3,145
3,558
6,518
3,425
1,928
5,625
6,192
Working Capital
1,066
1,061
687
592
580
6,522
6,513
5,935
5,936
4,872
7,828
6,604
6,614
7,188
4,882
6,577
6,562
LT Debt
5,449
6,427
6,964
8,621
10,814
9,375
12,129
12,598
13,032
13,339
10,686
10,960
13,388
14,799
16,716
18,257
18,652
Total Equity
16.29
18.61
17.59
21.54
28
27.41
24.22
15.36
24.18
30.37
18.59
14.57
12.26
7.76
8.44
8.4
7.86
Return on Invested Capital (%)
42.65
33.6
28.71
30
35.08
24.98
19.37
11.72
20.67
26.87
18.47
7.52
14.94
5.75
7.26
5.72
5.99
Return on Capital (%)
68.35
49.58
36.35
34.37
37.55
33.01
27.15
16.44
27.63
36
26.29
11.16
20.06
6.81
8.85
6.49
6.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
6,285
6,287
6,288
LT Finance Leases
305
290
273
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
147
147
148
Market Capitalization
- -
- -
21,138

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8,937
8,974
9,190
Cash, Cash Equivalents & STI
3,960
3,816
4,283
Accounts Receivable, Net
1,850
1,867
1,790
Inventories
2,209
2,168
1,949
Total Current Liabilities
3,290
3,349
2,999
Payables & Accruals
2,890
2,974
2,806
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
11.49%
9.22%
Free Cash Flow
8.37%
3.04%
-21.72%
Net Income, GAAP
4.09%
-1.48%
-20.79%
Sales/Revenue/Turnover
-0.48%
-5.68%
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,290
2,465
2,466
2,455
9,676
2025
2,431
2,646
2,535
2,279
9,891
2026
2,478
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.71
4.01
2.67
1.83
11.21
2025
1.65
4.33
3.18
-0.33
8.83
2026
2.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Novartis AG (NOVN.SW)
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS)
Roche Holding AG (RO.SW)
Grifols, S.A. (GIFOF)
Luye Pharma Group Ltd. (2186.HK)
Daiichi Sankyo Company, Limited (DSKYF)
Business
Biogen Inc. (Nasdaq: BIIB; SIX: BIIB) is a leading biotechnology company that discovers, develops, manufactures and commercializes therapies primarily for neurological and neurodegenerative diseases, as well as immunology and rare diseases; its core products include Tecfidera (dimethyl fumarate) and Vumerity (diroximel fumarate) for multiple sclerosis, Avonex (interferon beta-1a) and Plegridy (peginterferon beta-1a) for relapsing multiple sclerosis, Tysabri (natalizumab) for relapsing-remitting multiple sclerosis and Crohn's disease, Spinraza (nusinersen) for spinal muscular atrophy, and Leqembi (lecanemab-irmb, co-developed with Eisai) for early Alzheimer's disease. The company operates globally in the United States, Europe, Asia and other regions through direct sales forces, distributors and marketing groups, with manufacturing capabilities for complex biologics; it also offers biosimilars via its Samsung Bioepis joint venture. Founded in 1978 in Geneva, Switzerland by Nobel laureates Walter Gilbert and Phillip Sharp among others, with principal executive offices relocated to Cambridge, Massachusetts in 1982, Biogen merged with IDEC Pharmaceuticals in 2003 to form Biogen Idec, later reverting to Biogen Inc. Recent developments include the November 2025 completion of its acquisition of Alcyone Therapeutics for an upfront $85 million plus milestones to gain the ThecaFlex DRx drug delivery system under clinical study; a November 2025 partnership with Dayra Therapeutics featuring a $50 million upfront payment to develop oral macrocyclic peptides for immunological targets, with options to acquire candidates; a June 2025 R&D funding collaboration with Royalty Pharma providing up to $250 million for litifilimab development in exchange for royalties; and a prior $1.15 billion deal to acquire HI-Bio for immune therapies.